Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive Non-small Cell Lung Cancer Patients With Asymptomatic Brain Metastases

NCT04967417 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04967417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04967417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive Non-small Cell Lung Cancer Patients With Asymptomatic Brain Metastases
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 26, 2022
Completion date
December 2, 2024
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer